These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20472567)

  • 1. Calcium polymorphic ventricular tachycardia: a new name for CPVT?
    Brette F
    Cardiovasc Res; 2010 Jul; 87(1):10-1. PubMed ID: 20472567
    [No Abstract]   [Full Text] [Related]  

  • 2. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
    Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
    Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
    Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
    Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
    PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
    Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
    Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
    Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
    J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
    Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
    Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unzipping RyR2 in adult cardiomyocytes: getting closer to mechanisms of inherited ventricular arrhythmias?
    Fernandez-Velasco M; Gomez AM; Richard S
    Cardiovasc Res; 2006 Jun; 70(3):407-9. PubMed ID: 16690043
    [No Abstract]   [Full Text] [Related]  

  • 11. Impaired Binding to Junctophilin-2 and Nanostructural Alteration in CPVT Mutation.
    Yin L; Zahradnikova A; Rizzetto R; Boncompagni S; Rabesahala de Meritens C; Zhang Y; Joanne P; Marqués-Sulé E; Aguilar-Sánchez Y; Fernández-Tenorio M; Villejoubert O; Li L; Wang YY; Mateo P; Nicolas V; Gerbaud P; Lai FA; Perrier R; Álvarez JL; Niggli E; Valdivia HH; Valdivia CR; Ramos-Franco J; Zorio E; Zissimopoulos S; Protasi F; Benitah JP; Gómez AM
    Circ Res; 2021 Jul; 129(3):e35-e52. PubMed ID: 34111951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
    Katz G; Arad M; Eldar M
    Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts.
    Zhong X; Sun B; Vallmitjana A; Mi T; Guo W; Ni M; Wang R; Guo A; Duff HJ; Gillis AM; Song LS; Hove-Madsen L; Benitez R; Chen SR
    Biochem J; 2016 Nov; 473(21):3951-3964. PubMed ID: 27582498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
    Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
    Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.
    Terentyev D; Nori A; Santoro M; Viatchenko-Karpinski S; Kubalova Z; Gyorke I; Terentyeva R; Vedamoorthyrao S; Blom NA; Valle G; Napolitano C; Williams SC; Volpe P; Priori SG; Gyorke S
    Circ Res; 2006 May; 98(9):1151-8. PubMed ID: 16601229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
    Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
    Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation-linked, excessively tight interaction between the calmodulin binding domain and the C-terminal domain of the cardiac ryanodine receptor as a novel cause of catecholaminergic polymorphic ventricular tachycardia.
    Nishimura S; Yamamoto T; Nakamura Y; Kohno M; Hamada Y; Sufu Y; Fukui G; Nanno T; Ishiguchi H; Kato T; Xu X; Ono M; Oda T; Okuda S; Kobayashi S; Yano M
    Heart Rhythm; 2018 Jun; 15(6):905-914. PubMed ID: 29427818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ca2+-dependent modulation of voltage-gated myocyte sodium channels.
    Salvage SC; Habib ZF; Matthews HR; Jackson AP; Huang CL
    Biochem Soc Trans; 2021 Nov; 49(5):1941-1961. PubMed ID: 34643236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
    Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
    PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
    Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
    Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.